Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Europe Fights To Regenerate Its Abandoned Pharma R&D Sites

Executive Summary

Last month's announcement that Pfizer Inc. plans to close its flagship U.K. R&D operations in Sandwich, Kent, is but the latest example of how major shifts in Big Pharma's business and research strategies are exacting a heavy toll on long-established facilities.
Advertisement

Related Content

U.K. Life Sciences Minister Faces Hurdles To Plans To Speed Drug Access
NeRRe Therapeutics Spun Out Of GSK’s Unwanted Neuroscience Assets
Merck KGaA's Softly-Softly Approach To German Cutbacks Shows Learning From Swiss Experience
A-List Investor Spotlight
Prime Minister Cameron Plans To Boost U.K. Biotech With New "Catalyst" Fund, Early Patient Access Scheme
GSK Spins Out Pain Assets, Raises $35.4m
GSK Spins Out Pain Assets, Raises $35.4m

Topics

Advertisement
UsernamePublicRestriction

Register

PS053178

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel